IDEAS home Printed from https://ideas.repec.org/a/spr/eujhec/v16y2015i9p1005-1018.html
   My bibliography  Save this article

Health state utilities associated with attributes of treatments for hepatitis C

Author

Listed:
  • Louis Matza
  • Sandhya Sapra
  • John Dillon
  • Anupama Kalsekar
  • Evan Davies
  • Mary Devine
  • Jessica Jordan
  • Amanda Landrian
  • David Feeny

Abstract

Adverse events and greater treatment regimen complexity were associated with lower utility scores, suggesting a perceived decrease in quality of life beyond the impact of hepatitis C. The resulting utilities may be used in models estimating and comparing the value of treatments for hepatitis C. Copyright The Author(s) 2015

Suggested Citation

  • Louis Matza & Sandhya Sapra & John Dillon & Anupama Kalsekar & Evan Davies & Mary Devine & Jessica Jordan & Amanda Landrian & David Feeny, 2015. "Health state utilities associated with attributes of treatments for hepatitis C," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 16(9), pages 1005-1018, December.
    • Handle: RePEc:spr:eujhec:v:16:y:2015:i:9:p:1005-1018
    DOI: 10.1007/s10198-014-0649-6
    as

    Download full text from publisher

    File URL: http://hdl.handle.net/10.1007/s10198-014-0649-6
    Download Restriction: Access to full text is restricted to subscribers.
    File URL: https://libkey.io/10.1007/s10198-014-0649-6?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    As the access to this document is restricted, you may want to search for a different version of it.

    References listed on IDEAS

    as
    1. Brazier, John & Ratcliffe, Julie & Salomon, Joshua & Tsuchiya, Aki, 2016. "Measuring and Valuing Health Benefits for Economic Evaluation," OUP Catalogue, Oxford University Press, edition 2, number 9780198725923.
    2. Donna Rowen & John Brazier & Aki Tsuchiya & Tracey Young & Rachel Ibbotson, 2012. "It’s All in the Name, or Is It? The Impact of Labeling on Health State Values," Medical Decision Making, , vol. 32(1), pages 31-40, January.
    3. Anita J Brogan & Sandra E Talbird & James R Thompson & Jeffrey D Miller & Jaime Rubin & Baris Deniz, 2014. "Cost-effectiveness of Telaprevir Combination Therapy for Chronic Hepatitis C," PLOS ONE, Public Library of Science, vol. 9(3), pages 1-11, March.
    4. F. E. van Nooten & X. Koolman & W. B. F. Brouwer, 2009. "The influence of subjective life expectancy on health state valuations using a 10 year TTO," Health Economics, John Wiley & Sons, Ltd., vol. 18(5), pages 549-558, May.
    5. Jeremy Chancellor & Samuel Aballéa & Alison Lawrence & Rob Sheldon & Sandrine Cure & Juliette Plun-Favreau & Nick Marchant, 2008. "Preferences of Patients with Diabetes Mellitus for Inhaled versus Injectable Insulin Regimens," PharmacoEconomics, Springer, vol. 26(3), pages 217-234, March.
    6. Marra, Carlo A. & Woolcott, John C. & Kopec, Jacek A. & Shojania, Kamran & Offer, Robert & Brazier, John E. & Esdaile, John M. & Anis, Aslam H., 2005. "A comparison of generic, indirect utility measures (the HUI2, HUI3, SF-6D, and the EQ-5D) and disease-specific instruments (the RAQoL and the HAQ) in rheumatoid arthritis," Social Science & Medicine, Elsevier, vol. 60(7), pages 1571-1582, April.
    7. Victoria Brennan & Simon Dixon, 2013. "Incorporating Process Utility into Quality Adjusted Life Years: A Systematic Review of Empirical Studies," PharmacoEconomics, Springer, vol. 31(8), pages 677-691, August.
    8. Dolan, Paul, 1996. "Modelling valuations for health states: the effect of duration," Health Policy, Elsevier, vol. 38(3), pages 189-203, December.
    9. Trude Arnesen & Mari Trommald, 2005. "Are QALYs based on time trade‐off comparable? – A systematic review of TTO methodologies," Health Economics, John Wiley & Sons, Ltd., vol. 14(1), pages 39-53, January.
    10. Phil McEwan & Ray Kim & Yong Yuan, 2013. "Assessing the Cost Utility of Response-Guided Therapy in Patients with Chronic Hepatitis C Genotype 1 in the UK Using the MONARCH Model," Applied Health Economics and Health Policy, Springer, vol. 11(1), pages 53-63, February.
    11. Kristina Boye & Louis Matza & Kimberly Walter & Kate Brunt & Andrew Palsgrove & Aodan Tynan, 2011. "Utilities and disutilities for attributes of injectable treatments for type 2 diabetes," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 12(3), pages 219-230, June.
    12. David J. McLernon & John Dillon & Peter T. Donnan, 2008. "Systematic Review: Health-State Utilities in Liver Disease: A Systematic Review," Medical Decision Making, , vol. 28(4), pages 582-592, July.
    13. Louis Matza & Karen Chung & Kate Brunt & John Brazier & Ada Braun & Brooke Currie & Andrew Palsgrove & Evan Davies & Jean-Jacques Body, 2014. "Health state utilities for skeletal-related events secondary to bone metastases," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 15(1), pages 7-18, January.
    Full references (including those not matched with items on IDEAS)

    Citations

    Citations are extracted by the CitEc Project, subscribe to its RSS feed for this item.
    as


    Cited by:

    1. Louis S. Matza & Katherine J. Kim & Holly Yu & Katherine A. Belden & Antonia F. Chen & Mark Kurd & Bruce Y. Lee & Jason Webb, 2019. "Health state utilities associated with post-surgical Staphylococcus aureus infections," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 20(6), pages 819-827, August.
    2. Louis S. Matza & L. Clark Paramore & Katie D. Stewart & Hayley Karn & Minesh Jobanputra & Andrew C. Dietz, 2020. "Health state utilities associated with treatment for transfusion-dependent β-thalassemia," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 21(3), pages 397-407, April.

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. Arthur Attema & Yvette Edelaar-Peeters & Matthijs Versteegh & Elly Stolk, 2013. "Time trade-off: one methodology, different methods," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 14(1), pages 53-64, July.
    2. Louis S. Matza & Kristina S. Boye & David H. Feeny & Lee Bowman & Joseph A. Johnston & Katie D. Stewart & Kelly McDaniel & Jessica Jordan, 2016. "The time horizon matters: results of an exploratory study varying the timeframe in time trade-off and standard gamble utility elicitation," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 17(8), pages 979-990, November.
    3. Brazier, JE & Yang, Y & Tsuchiya, A, 2008. "A review of studies mapping (or cross walking) from non-preference based measures of health to generic preference-based measures," MPRA Paper 29808, University Library of Munich, Germany.
    4. Constanza L Vargas & Manuel A Espinoza & Andrés Giglio & Alejandro Soza, 2015. "Cost Effectiveness of Daclatasvir/Asunaprevir Versus Peginterferon/Ribavirin and Protease Inhibitors for the Treatment of Hepatitis c Genotype 1b Naïve Patients in Chile," PLOS ONE, Public Library of Science, vol. 10(11), pages 1-16, November.
    5. Georgina Jones & Victoria Brennan & Richard Jacques & Hilary Wood & Simon Dixon & Stephen Radley, 2018. "Evaluating the impact of a ‘virtual clinic’ on patient experience, personal and provider costs of care in urinary incontinence: A randomised controlled trial," PLOS ONE, Public Library of Science, vol. 13(1), pages 1-16, January.
    6. Peasgood, T & Ward, S & Brazier, J, 2010. "A review and meta-analysis of health state utility values in breast cancer," MPRA Paper 29950, University Library of Munich, Germany.
    7. Floortje Nooten & Jan Busschbach & Michel Agthoven & Job Exel & Werner Brouwer, 2018. "What should we know about the person behind a TTO?," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 19(9), pages 1207-1211, December.
    8. Arthur Attema & Werner Brouwer, 2012. "The way that you do it? An elaborate test of procedural invariance of TTO, using a choice-based design," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 13(4), pages 491-500, August.
    9. R. Hoorn & A. Donders & M. Oppe & P. Stalmeier, 2014. "The Better than Dead Method: Feasibility and Interpretation of a Valuation Study," PharmacoEconomics, Springer, vol. 32(8), pages 789-799, August.
    10. Julie Ratcliffe & Terry Flynn & Frances Terlich & Katherine Stevens & John Brazier & Michael Sawyer, 2012. "Developing Adolescent-Specific Health State Values for Economic Evaluation," PharmacoEconomics, Springer, vol. 30(8), pages 713-727, August.
    11. Patricia Cubi-Molla & Koonal Shah & Kristina Burström, 2018. "Experience-Based Values: A Framework for Classifying Different Types of Experience in Health Valuation Research," The Patient: Patient-Centered Outcomes Research, Springer;International Academy of Health Preference Research, vol. 11(3), pages 253-270, June.
    12. Mark Oppe & Kim Rand-Hendriksen & Koonal Shah & Juan M. Ramos‐Goñi & Nan Luo, 2016. "EuroQol Protocols for Time Trade-Off Valuation of Health Outcomes," PharmacoEconomics, Springer, vol. 34(10), pages 993-1004, October.
    13. Louis S. Matza & L. Clark Paramore & Katie D. Stewart & Hayley Karn & Minesh Jobanputra & Andrew C. Dietz, 2020. "Health state utilities associated with treatment for transfusion-dependent β-thalassemia," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 21(3), pages 397-407, April.
    14. Louis S. Matza & Katie D. Stewart & Marie Fournier & Donna Rowen & Robin Lachmann & Maurizio Scarpa & Eugen Mengel & Travis Obermeyer & Evren Ayik & Fernando Laredo & Ruth Pulikottil-Jacob, 2024. "Assessment of health state utilities associated with adult and pediatric acid sphingomyelinase deficiency (ASMD)," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 25(8), pages 1437-1448, November.
    15. Louis Matza & Karen Chung & Kate Brunt & John Brazier & Ada Braun & Brooke Currie & Andrew Palsgrove & Evan Davies & Jean-Jacques Body, 2014. "Health state utilities for skeletal-related events secondary to bone metastases," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 15(1), pages 7-18, January.
    16. Jeremy Chancellor & Samuel Aballéa & Alison Lawrence & Rob Sheldon & Sandrine Cure & Juliette Plun-Favreau & Nick Marchant, 2008. "Preferences of Patients with Diabetes Mellitus for Inhaled versus Injectable Insulin Regimens," PharmacoEconomics, Springer, vol. 26(3), pages 217-234, March.
    17. Nick Bansback & Huiying Sun & Daphne P. Guh & Xin Li & Bohdan Nosyk & Susan Griffin & Paul G. Barnett & Aslam H. Anis, 2008. "Impact of the recall period on measuring health utilities for acute events," Health Economics, John Wiley & Sons, Ltd., vol. 17(12), pages 1413-1419.
    18. Joanna Coast & Hareth Al‐Janabi & Eileen J. Sutton & Susan A. Horrocks & A. Jane Vosper & Dawn R. Swancutt & Terry N. Flynn, 2012. "Using qualitative methods for attribute development for discrete choice experiments: issues and recommendations," Health Economics, John Wiley & Sons, Ltd., vol. 21(6), pages 730-741, June.
    19. Joanna M Charles & Deirdre M Harrington & Melanie J Davies & Charlotte L Edwardson & Trish Gorely & Danielle H Bodicoat & Kamlesh Khunti & Lauren B Sherar & Thomas Yates & Rhiannon Tudor Edwards, 2019. "Micro-costing and a cost-consequence analysis of the ‘Girls Active’ programme: A cluster randomised controlled trial," PLOS ONE, Public Library of Science, vol. 14(8), pages 1-17, August.
    20. Mohamed N.M.T. Al Khayat & Job F.H. Eijsink & Maarten J. Postma & Jan C. Wilschut & Marinus van Hulst, 2020. "The Cost-Effectiveness of Hepatitis C Virus Screening Strategies among Recently Arrived Migrants in the Netherlands," IJERPH, MDPI, vol. 17(17), pages 1-13, August.

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:spr:eujhec:v:16:y:2015:i:9:p:1005-1018. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.springer.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.